These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 11699832

  • 1. Influence of dissolution medium agitation on release profiles of sustained-release tablets.
    Paulo, Sousa Lobo JM.
    Drug Dev Ind Pharm; 2001 Sep; 27(8):811-7. PubMed ID: 11699832
    [Abstract] [Full Text] [Related]

  • 2. Divisability of diltiazem matrix sustained-release tablets.
    Costa P, Sousa Lobo JM.
    Pharm Dev Technol; 2001 Aug; 6(3):343-51. PubMed ID: 11485176
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Drug release kinetic analysis and prediction of release data via polymer molecular weight in sustained release diltiazem matrices.
    Adibkia K, Ghanbarzadeh S, Mohammadi G, Khiavi HZ, Sabzevari A, Barzegar-Jalali M.
    Drug Res (Stuttg); 2014 Mar; 64(3):118-23. PubMed ID: 23986307
    [Abstract] [Full Text] [Related]

  • 6. Assessment of xanthan gum based sustained release matrix tablets containing highly water-soluble propranolol HCl.
    Ali A, Iqbal M, Akhtar N, Khan HM, Ullah A, Uddin M, Khan MT.
    Acta Pol Pharm; 2013 Mar; 70(2):283-9. PubMed ID: 23614284
    [Abstract] [Full Text] [Related]

  • 7. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
    Avramoff A, Domb AJ.
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z, Fassihi R.
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [Abstract] [Full Text] [Related]

  • 11. Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride.
    Chen S, Zhu J, Cheng J.
    Pharmazie; 2007 Dec; 62(12):907-13. PubMed ID: 18214341
    [Abstract] [Full Text] [Related]

  • 12. Design of floating bilayer tablets of diltiazem hydrochloride and lovastatin.
    Kulkarni AS, Bhatia MS.
    PDA J Pharm Sci Technol; 2008 Dec; 62(5):344-52. PubMed ID: 19055230
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel use of similarity factors f2 and Sd for the development of diltiazem HCl modified-release tablets using a 3(2) factorial design.
    Gohel MC, Panchal MK.
    Drug Dev Ind Pharm; 2002 Jan; 28(1):77-87. PubMed ID: 11858527
    [Abstract] [Full Text] [Related]

  • 18. In vitro release studies of furosemide reference tablets: influence of agitation rate, USP apparatus, and dissolution media.
    Medina-López R, Guillén-Moedano S, Hurtado M.
    ADMET DMPK; 2020 Jan; 8(4):411-423. PubMed ID: 35300193
    [Abstract] [Full Text] [Related]

  • 19. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR, Paim CS, Steppe M, Schapoval EE.
    J Pharm Pharm Sci; 2005 Aug 11; 8(2):289-98. PubMed ID: 16124939
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.